Columvi Solution, Concentrate
NDC 50242-125
Product Information
Columvi (glofitamab) is a BLA-approved product labeled by Genentech, Inc.. This medication is typically used as a bispecific cd20-directed cd3 t cell engager [epc]. It is supplied as a solution, concentrate for intravenous administration. This product entry covers the primary NDC 50242-125 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 50242-125?
What are the uses of this product?
What are Active Ingredients of this product?
- GLOFITAMAB 2.5 mg/2.5mL - T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- GLOFITAMAB (UNII: 06P3KLK2J8)
- GLOFITAMAB (UNII: 06P3KLK2J8) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HISTIDINE (UNII: 4QD397987E)
- HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE (UNII: X573657P6P)
- METHIONINE (UNII: AE28F7PNPL)
- SUCROSE (UNII: C151H8M554)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2639786 - glofitamab-gxbm 10 MG in 10 ML Injection
- RxCUI: 2639786 - 10 ML glofitamab-gxbm 1 MG/ML Injection
- RxCUI: 2639786 - glofitamab-gxbm 10 MG per 10 ML Injection
- RxCUI: 2639792 - Columvi 10 MG in 10 ML Injection
- RxCUI: 2639792 - 10 ML glofitamab-gxbm 1 MG/ML Injection [Columvi]
Which are the Pharmacologic Classes of this product?
- Bispecific CD20-directed CD3 T Cell Engager - [EPC] (Established Pharmacologic Class)
- CD20-directed Antibody Interactions - [MoA] (Mechanism of Action)
- CD3 Receptor Agonists - [MoA] (Mechanism of Action)
- CD3-directed Antibody Interactions - [MoA] (Mechanism of Action)
- Cytochrome P450 Inhibitors - [MoA] (Mechanism of Action)
- Increased Cytokine Activity - [PE] (Physiologic Effect)
* Please review the full disclaimer at the bottom of this page.